Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2009, Henlius has made significant strides in the biotechnology, healthcare, and pharmaceutical industries. The company has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product lifecycle including R&D, manufacturing, and commercialization. Henlius has proactively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as a backbone. The company has also leveraged its capabilities to develop biosimilars such as HANLIKANG, HANQUYOU, HANDAYUAN, and HANBEITAI, with approvals in various global markets. Notably, Henlius has received a significant $156.00M Venture Round investment from investors including New China Capital Management, Loyal Valley Capital, CICC, and GreenTomato in July 2018. With 5 products launched in China, 3 approved for marketing in overseas markets, and 23 indications approved worldwide, Henlius has demonstrated its potential on a global scale. The company's commitment to advancing treatments is further underscored by its conduct of over 30 clinical studies for 16 products globally, expanding its presence in major as well as emerging markets. Henlius' dedication to reliable quality and affordable innovation aligns with the growing demand for accessible biopharmaceutical solutions, positioning the company for continued success in the industry.